Metraipolis › archive › dc_72e9cd96b164
Explore the efficacy of microwave ablation combined with fruquintinib and tislelizumab in the treatment of metastatic colorectal cancer — Europe PMC PMID:41815543
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41815543
- DOI
- 10.3389/fonc.2026.1728876
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-05T13:13:47.319Z
- SHA-256 of the archived text
e2852292798f95f310adec9a7f1c19811ceccb4bad3f51419a2944bac7470964- Stable URL of this page
https://metraipolis.com/documento/dc_72e9cd96b164
How to cite
Explore the efficacy of microwave ablation combined with fruquintinib and tislelizumab in the treatment of metastatic colorectal cancer — Europe PMC PMID:41815543 — Europe PMC (en), https://europepmc.org/article/MED/41815543 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_72e9cd96b164 (Metraipolis archive dc_72e9cd96b164, sha256 e2852292798f95f310adec9a7f1c19811ceccb4bad3f51419a2944bac7470964)
BibTeX
@misc{dc72e9cd96b164,
title = {Explore the efficacy of microwave ablation combined with fruquintinib and tislelizumab in the treatment of metastatic colorectal cancer — Europe PMC PMID:41815543},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41815543},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_72e9cd96b164; sha256 e2852292798f95f310adec9a7f1c19811ceccb4bad3f51419a2944bac7470964},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41815543. Agents can read the archived copy with the MCP tool read_document.